Pay in 4 interest-free payments of $5.72 Learn more
Ships within 48 hours · Estimated delivery Oct 8 - Oct 13
In a February 26, 2025 warning letter to a peptide seller, FDA found that website claims describing semaglutide and tirzepatide products in clinical terms established the products' intended use as drugs for human use under 21 CFR 201.128 , regardless of the research-use disclaimer
However, this is controversial and not fully conclusive
The lot number ties directly to the corresponding COA, which is available on request for any researcher who needs to file documentation against a study protocol or institutional review process
Johns Wort have blood-thinning effects
or yellow label (contains 4 doses of 2 mg maintenance dose)
US$ 28.45
US$ 28.15
US$ 21.77
